- About Lung Cancer
- Support & Resources
- Make a Difference
February 20, 2009—President Obama has signed and approved The American Recovery and Reinvestment Act of 2009 with new language reflecting the negotiations between the House and Senate versions. Many of the changes that will affect public health policy come from Senate and House negotiations over short term supplemental funding for NIH.
The bill contains $10.4 billion for NIH, available through September 2010. This raises the initial investment in NIH in the House version by $6.5B. These funds, while still in the administrative and planning stage, will be loosely dispersed as follows, according to Dr. Raynard Kington, Acting Director of NIH:
NIH will view this $10.4B as supplemental to its annual $26B budget and will be directed entirely to research that can be reviewed, funded and underway prior to the September 2010 deadline. These funds will be dispersed and directed in one of three ways: using existing RO1 mechanisms and proposals, supplementing existing grants (following usual NIH procedures), or through a new program known as the NIH Challenge Grant Program (NCGP). The NCGP will provide up to $500K/year for two years for groundbreaking research with a focus on new and young researchers. Roughly $100-200M is expected to be dispersed using the NCGP.
The American Recovery and Reinvestment Act of 2009 has also designated $1.1B total for comparative effectiveness research. Of that amount;
These funds, according to language in the bill, are intended to "support research that evaluates and compares the clinical effectiveness, risk and benefits of two or more medical treatments and services."
In addition the bill has specific provision for the following:
Lung Cancer Alliance will continue to update you on the stimulus package and its effect on public health as more details emerge.